Escitalopram versus citalopram: The surprising role of the R-enantiomer

Psychopharmacology

Volumn 174, Issue 2, 2004, Pages 163-176

  Sánchez, Connie ^a   Bøgesó, Klaus P ^a   Ebert, Bjarke ^a   Reines, Elin Heldbo ^a   Braestrup, Claus ^a  

^a H LUNDBECK A S   (Denmark)

Author keywords

Antidepressant; Citalopram; Depression; Enantiomers; Escitalopram; Panic disorder; R citalopram; Serotonin transporter; SSRI; Stereochemistry

Indexed keywords

1 METHYL 5 PHENYL 5 PROPYLBARBITURIC ACID; 2 AMINO 3 (3 HYDROXY 5 PHENYLISOXAZOL 4 YL)PROPIONIC ACID; 3BETA (4 IODOPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; AMPA RECEPTOR AGONIST; ANTIDEPRESSANT AGENT; BARBITURIC ACID DERIVATIVE; CITALOPRAM; DELTA OPIATE RECEPTOR AGONIST; ESCITALOPRAM; FLUOXETINE; MIANSERIN; MIRTAZAPINE; MU OPIATE RECEPTOR AGONIST; PICENADOL; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG; VENLAFAXINE;

ALLOSTERISM; BINDING AFFINITY; BLOOD BRAIN BARRIER; CLINICAL TRIAL; DISEASE SEVERITY; DOSE RESPONSE; DRUG ACTIVITY; DRUG CLEARANCE; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG INHIBITION; DRUG MECHANISM; DRUG PENETRATION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENANTIOMER; HUMAN; IC 50; MAJOR DEPRESSION; NONHUMAN; PANIC; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; STEREOCHEMISTRY; TRANQUILIZING ACTIVITY; TREATMENT OUTCOME;

ANIMALS; BEHAVIOR, ANIMAL; BRAIN; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; DRUG INTERACTIONS; HUMANS; MICE; PANIC DISORDER; RANDOMIZED CONTROLLED TRIALS; RATS; SEROTONIN UPTAKE INHIBITORS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 3142756613     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (89)

1. Agranat I, Caner H, Caldwell J (2002) Putting chirality to work: the strategy of chiral switches. Nat Rev Drug Discov 1:753-768
2. Allan AM, Harris RA (1986) Anesthetic and convulsant barbiturates alter gamma-aminobutyric acid-stimulated chloride flux across brain membranes. J Pharmacol Exp Ther 238:763-768
3. Attenburrow MJ, Mitter PR, Whale R, Terao T, Cowen PJ (2001) Low-dose citalopram as a 5-HT neuroendocrine probe. Psychopharmacology 155:323-326
4. Auquier P, Robitail S, Llorca P-M, Rive B (2003) Comparison of escitalopram and citalopram efficacy: a meta-analysis. Int J Psychiatr Clin Pract 7:259-268
5. Berglund RA (1994) Asymmetric synthesis. US Patent 5362886, 8 Nov 1994, p 3
6. Bien E, Gruca P, Papp M (2003) R-Citalopram attenuates the anxiolytic-like activity of escitalopram in two animal models. Behav Pharmacol 14:S37
7. Blackburn TP, Foster GA, Greenwood DT, Howe R (1978) Effects of viloxazine, its optical isomers and its major metabolites on biogenic amine uptake mechanisms in vitro and in vivo. Eur J Pharmacol 52:367-374
8. 2- selective adrenoreceptor antagonist org 3770 (mirtazapine, Remeron) enhances noradrenergic and serotonergic transmission. Hum Psychopharmacol Clin Exp 10(Suppl 2):107-118
9. 125I]RTI-55 to dopamine and serotonin transporters in rat brain. Synapse 12:27-36
10. Borsini F (1995) Role of the serotonergic system in the forced swimming test. Neurosci Biobehav Rev 19:377-395
11. Borsini F, Podhorna J, Marazziti D (2002) Do animal models of anxiety predict anxiolytic-like effects of antidepressants? Psychopharmacology 163:121-141
12. Brøsen K, Naranjo CA (2001) Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram. Eur Neuropsychopharmacol 11:275-283
13. Burke WJ (2001) Fixed dose study of escitalopram in the treatment of depression. Abstract and poster 518 presented at the annual meeting of the American Psychiatric Association, May 5-10, 2001, New Orleans
14. Burke WJ, Gergel I, Bose A (2002) Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 63:331-336
15. Carter RB, Dykstra LA (1984) Quantitative analysis of the interaction between the agonist and antagonist isomers of picenadol (LY150720) on electric shock titration in the squirrel monkey. Eur J Pharmacol 106:469-476
16. Chen F, Larsen MB, Sánchez C, Wiborg O (2003) The S-enantiomer of citalopram increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors. Eur Neuropsychopharmacol 13:S217
17. Colonna L, Reines EH, Andersen HF (2002) Escitalopram is well tolerated and more efficacious than citalopram in long-term treatment of moderately depressed patients. Int J Psychol Clin Prac 6:243-244
18. Cremers TIFH, Westerink BHC (2003) Pharmacological difference between escitalopram and citalopram. Int J Psychiatr Clin Prac 7:306
19. Cryan JF, Markou A, Lucki I (2002) Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol Sci 23:238-245
20. Danchev ND, Rozhanets W, Zhmurenko LA, Glozman OM, Zagoreversuskii VA, Valdman AV (1984) Byulleten Eksperimental'noi Biologii I Meditsiny 97:576-578
21. Delbressine LPC, Moonen MEG, Kaspersen FM, Wagenaars GN, Jacobs PL, Timmer CJ, Paanakker JE, Van Hal HJM, Voortman G (1998) Pharmacokinetics and biotransformation of mirtazapine in human volunteers. Clin Drug Invest 15:45-55
22. Deprez D, Chassard D, Baille P, Mignot A, Ung HL, Puozzo C (1998) Which bioequivalence study for a racemic drug? Application to milnacipran. Eur J Drug Metab Pharmacokinet 23:166-171
23. DeVane CL (2002) Refining current therapies: clinical implications to the treatment of depression. Molecules and mood disorders: drug discovery and the treatment of depression. Program and abstracts of the American Psychiatric Association 155th annual meeting, May 18-23 2002, Philadelphia, Pa.
24. Dodd S, Boulton DW, Burrows GD, DeVane CL, Norman TR (2001) In vitro metabolism of mirtazapine enantiomers by human cytochrome P450 enzymes. Hum Psychopharmacol 16:541-544
25. Eap CB, Powell K, Campussouche D, Monney C, Baettig D, Taeschner W, Baumann P (1995) Determination of the enantiomers of mianserin, desmethylmianserin, and 8-hydroxymianserin in the plasma and urine of mianserin-treated patients. Chirality 6:555-563
26. Ebert B, Lenz S, Brehm L, Bregnedal P, Hansen JJ, Frederiksen K, Bøgesø KP, Krogsgaard-Larsen P (1994) Resolution, absolute stereochemistry, and pharmacology of the S-(+)- and R-(-)-isomers of the apparent partial AMPA receptor agonist (R,S)-2-amino-3-(3-hydroxy-5- phenylisoxazol-4-yl)propionic acid [(R, S)-APPA]. J Med Chem 37:878-884
27. Fish EW, Faccidomo S, Gupta S, Miczek KA (2004) Anxiolytic-like effects of escitalopram, citalopram and R-citalopram in maternally separated mouse pups. J Pharmacol Exp Ther 308:474-480
28. Foglia JP, Pollock BG, Kirshner MA, Rosen J, Sweet R, Mulsant B (1997) Plasma levels of citalopram enantiomers and metabolites in elderly patients. Psychopharmacol Bull 33:109-112
29. Frigerio E, Pianezzola E, Strolin Benedetti M (1994) Sensitive procedure for the determination of reboxetine enantiomers in human plasma by reversed phase HPLC with fluorimetric detection after chiral derivatization with (+)-1-(9-fluorenyl) ethyl chloroformate. J Chromatogr A 660:351-358
30. Fuller RW, Perry KW, Hemrick-Luecke SK, Engleman E (1996) Serum corticosterone increases reflect enhanced uptake inhibitor-induced elevation of extracellular 5-hydroxvtryptamine in rat hypothalamus. J Pharm Pharmacol 48:68-70
31. Gumnick JF, Nemeroff CB (2000) Problems with currently available antidepressants. J Clin Psychiatry 61(Suppl 10):5-15
32. Guy W (1976) ECDEU assessment manual for psychopharmacology (rev. 1976) Biometric Laboratory. The George Washington University, Kensington, Md. US Department of Health, Education, and Welfare, DHEW publication no. (ADM) 218-222
33. Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62
34. Hand TH, Marek GJ, Seiden LS (1991) Comparison of the effects of mianserin and its enantiomers and metabolites on a behavioral screen for antidepressant activity. Psychopharmacology 105:453-458
35. Hascoët M, Bourin M, Dhonnchadha BAN (2001) The mouse light-dark paradigm: a review. Prog Neuropsychopharmacol Biol Psychiatry 25:141-166
36. Hogg S, Sánchez C (1999) The antidepressant effects of citalopram are mediated by the S-(+)- and not the R-(-)-enantiomer. Eur Neuropsychopharmacol 9(Suppl 1):S213
37. Howe R, Leigh T, Rao BS, Todd AH (1976) Optical isomers of 2-(2-ethoxyphenoxymethyl)tetrahydro-1,4-oxazine (viloxazine) and related compounds. J Med Chem 19:1074-1076
38. Hyttel J, Bøgesø KP, Perregaard J, Sánchez C (1992) The pharmacological effect of citalopram resides in the (S)-(+)-enantiomer. J Neural Transm [Gen Sect] 88:157-160
39. Jørgensen H, Knigge U, Kjaer A, Warberg J (1996) Interactions of histaminergic and serotonergic neurons in the hypothalamic regulation of prolactin and ACTH secretion. Neuroendocrinology 64:329-336
40. Keller MB (2000) Citalopram therapy for depression: a review of 10 years of European experience and data from US clinical trials. J Clin Psychiatry 61:896-908
41. 3 receptors in cultured mouse neuroblastoma cells. Neuropharmacology 33:501-507
42. Lane RM, Baker GB (1999) Chirality and drugs used in psychiatry: nice to know or need to know? Cell Mol Neurobiol 19:355-372
43. 3H-MADAM binding to 5-hydroxytryptamine transporters in vitro and in vivo in mice; correlation with behavioural effects. Br J Pharmacol 141:1015-1023
44. Leander JD, Hart JC, Lochner MA, Hynes MD III, Zimmerman DM (1982) Novel phenylpiperidine opioid antagonists and partial agonists: effects on fluid consumption. Eur J Pharmacol 81:185-192
45. Lepola UM, Loft H, Reines EH (2003) Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 18:211-217
46. Lepola U, Wade W, Andersen HF (2004) Do equivalent doses of escitalopram and citalopram have similar efficacy? - a pooled analysis of two positive placebo-controlled studies in major depressive disorder. Int Clin Psychopharmacol (in press)
47. Lin EH, Von-Korff M, Katon W, Bush T, Simon GE, Walker E, Robinson P (1995) The role of the primary care physician in patients' adherence to antidepressant therapy. Med Care 33:67-74
48. Lucki I, Brown K (2003) Different roles of the enantiomers of citalopram on serotonin transmission. Biol Psychiatry 53:45S
49. McGrath C, Burrows GD, Norman TR (1998) Neurochemical effects of the enantiomers of mirtazapine in normal rats. Eur J Pharmacol 356:121-126
50. 11C]DASB PET imaging study. Am J Psychiatry 158:1843-1849
51. Mitchell PJ, Hogg S (2001) Behavioural effects of escitalopram predict potent antidepressant activity. Biol Psychiatry 49:115S
52. Mitchell PJ, Hogg S (2002) Effects of escitalopram (S-(+)-citalopram) in the resident-intruder model of antidepressant drug activity. J Psychopharmacol 16:A42
53. Montgomery SA, Åsberg M (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382-389
54. Montgomery SA, Loft H, Sánchez C, Reines EH, Papp M (2001) Escitalopram (S-enantiomer of citalopram): clinical efficacy and onset of action predicted from a rat model. Pharmacol Toxicol 88:282-286
55. Mørk A, Kreilgaard M, Sánchez C (2003) The R-enantiomer of citalopram counteracts escitalopram-induced increase in extracellular 5-HT in the frontal cortex of freely moving rats. Neuropharmacology 45:167-173
56. Muth EA, Haskins JT, Moyer JA et al (1986) Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative. Biochem Pharmacol 35:4493-4497
57. Owens MJ, Knight DL, Nemeroff CB (2001) Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry 50:345-350
58. Pinder RM, Van-Delft AM (1983) The potential therapeutic role of the enantiomers and metabolites of mianserin. Br J Clin Pharmacol 15:269S-276S
59. 3H]paroxetine binding to platelet and neuronal membranes. Eur J Pharmacol 119:1-8
60. Plenge P, Mellerup ET, Honoré T, le Fèvre Honoré P (1987) The activity of 25 paroxetine/femoxetine structure variants in various reactions, assumed to be important for the effect of antidepressants. J Pharm Pharmacol 39:877-882
61. 3H] citalopram binding to the 5-HT transporter from brain and platelets. Eur J Pharmacol 206:243-250
62. Raap DK, Van de Kar LD (1999) Selective serotonin reuptake inhibitors and neuroendocrine function. Life Sci 65:1217-1235
63. Rochat B, Baumann P, Audus KL (1999) Transport mechanisms for the antidepressant citalopram in brain microvessel endothelium. Brain Res 831:229-236
64. Sánchez C (2003a) R-citalopram attenuates anxiolytic effects of escitalopram in a rat ultrasonic vocalisation model. Eur J Pharmacol 464:155-158
65. Sánchez C (2003b) Stress-induced vocalisation in adult animals. A valid model of anxiety? Eur J Pharmacol 463:133-143
66. 1A receptors. Eur J Pharmacol 264:241-247
67. Sánchez C, Kreilgaard M (2004) R-citalopram inhibits functional and 5-HTP-evoked behavioural responses to the SSRI, escitalopram. Pharmacol Biochem Behav 77:391-398
68. Sánchez C, Bergqvist PBF, Brennum LT, Gupta S, Hogg S, Larsen A, Wiborg O (2003a) Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities. Psychopharmacology 167:353-362
69. Sánchez C, Gruca P, Bien E, Papp M (2003b) R-citalopram counteracts the effect of escitalopram in a rat conditioned fear stress model of anxiety. Pharmacol Biochem Behav 75:903-907
70. Sánchez C, Gruca P, Papp M (2003c) R-citalopram counteracts the antidepressant-like effect of escitalopram in a rat chronic mild stress model. Behav Pharmacol 14:465-470
71. Sidhu J, Priskorn M, Poulsen M, Segonzac A, Grollier G, Larsen F (1997) Steady-state pharmacokinetics of the enantiomers of citalopram and its metabolites in humans. Chirality 9:686-692
72. Stahl S, Gergel I, Li D (2003) Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 64:1322-1327
73. Stevens JC, Wrighton SA (1993) Interaction of the enantiomers of fluoxetine and norfluoxetine with human liver cytochromes P450. J Pharmacol Exp Ther 266:964-971
74. Stórustovu S, Sánchez C, Pörzgen P, Brennum LT, Larsen AK, Pulis M, Ebert B (2004) R-Citalopram functionally antagonizes escitalopram in vivo and in vitro: evidence for kinetic interaction at the serotonin transporter. Br J Pharmacol (in press)
75. Strolin B, Frigerio E, Tocchetti P, Brianceschi G, Castelli MG, Pellizzoni C, Dostert P (1995) Stereoselective and species-dependent kinetics of reboxetine in mouse and rat. Chirality 7:285-289
76. Ticku MK, Rastogi SK, Thyagarajan R (1985) Separate site(s) of action of optical isomers of 1-methyl-5-phenyl-5-propylbarbituric acid with opposite pharmacological activities at the GABA receptor complex. Eur J Pharmacol 112:1-9
77. Tucker GT (2000) Chiral switches. Lancet 355:1085-1087
78. Welch WM (1995) Discovery and preclinical development of the serotonin reuptake inhibitor sertraline. In: Maryanoff BE, Maryanoff CA (eds) Advances of medicinal chemistry. JAI, London, pp 113-148
79. Welch WM, Kraska AR, Sarges R, Koe B K (1984) Nontricyclic antidepressant agents derived from cis- and trans-1-amino-4-aryltetralins. J Med Chem 27:1508-1515
80. Wennogle LP, Meyerson LR (1985) Serotonin uptake inhibitors differentially modulate high affinity imipramine dissociation in human platelet membranes. Life Sci 36:1541-1550
81. 3H]-S-citalopram with the human serotonin transporter by an allosteric mechanism. Eur Neuropsychopharmacol 13:S217
82. Willner P (1991) Animal models as simulations of depression. Trends Pharmacol Sci 12:131-136
83. Willner P (1997) Validity, reliability and utility of the chronic mild stress model of depression: a 10-year review and evaluation. Psychopharmacology 134:319-329
84. Wong DT, Bymaster FP, Ried LR, Mayle DA, Krushinski JH, Robertson DW (1993a) Norfluoxetine enantiomers as inhibitors of serotonin uptake in rat brain. Neuropsychopharmacology 8:337-344
85. Wong DT, Bymaster FP, Mayle DA, Reid LR, Krushinski JH, Robertson DW (1993b) LY248686, a new inhibitor of serotonin and norepinephrine uptake. Neuropsychopharmacology 8:23-33
86. Wong DT, Bymaster FP, Engleman EA (1995) Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: twenty years since its first publication. Life Sci 57:411-441
87. 3 receptors. J Pharm Pharmacol 45:711-714
88. Yardley JP, Morris-Husbands GE, Stack G, Butch J, Bicksler J, Moyer JA, Muth EA, Andree T, Fletcher H III, James MNG, Sielecki AR (1990) 2-Phenyl-2-(1-hydroxycycloalkyl)ethylamine derivatives: synthesis and antidepressant activity. J Med Chem 33:2899-2905
89. Zheng Z, Jamour M, Klotz U (2000) Stereoselective HPLC-assay for citalopram and its metabolites. Ther Drug Monit 22:219-224